

Products approved by the Food and Drug Administration of Iran in the field of reconstructive medicine

No.	Product Name	Manufacturer	Product Specifications	Current Indication	Indication during Clinical trial	Date of GMP Certification Acquisition	Price (Million IRR)	IDL
1	ReColorCell	CELLTECH PHARMED	Autologous Melanocytes cells	Vitiligo	–	2018	90	+
2	Renewderm Cell	CELLTECH PHARMED	Autologous Fibroblasts cells	Wrinkle, Scar, Acne	–	2018	350	-
3	MesestroCell	CELLTECH PHARMED	Autologous Mesenchyme Cells, Derived from the brain bone	Osteoarthritis	–	2018	200	-
4	Vartocell	CELLTECH PHARMED	Allogeneic Mesenchyme Cells, Derived from umbilical cord	Cerebral Palsy	-Osteoarthritis - Premature Ovary failure (POF) - heart attack - ALS - GvHD - Primary sclerosing Cholangitis (PSC) - Fatty Liver (NASH)	2020	100 (for each Vial that Contains 20 Million Cell)	-
5	Monucell	CELLTECH PHARMED	Single Core cells autologous, Derived from bone marrow	–	_ Stroke and Heart failure _ Vascular insufficiency	in progress	–	-

Products approved by the Food and Drug Administration of Iran in the field of reconstructive medicine

6	Stem Sin	Sinacell	Autolog Mesenchyme Cells, Derived from the brain bone	MS	Waiting for CTA confirmation, Phase I	2018	–	-
7	Allo Stem Sin	Sinacell	Allogeneic Mesenchyme Cells, Derived from umbilical cord	ALS	Waiting for CTA confirmation, Phase II/III	2018	–	–
8	Sina Derm	Sinacell	Allogeneic Fibroblasts Cells, Derived from foreskin	Wound dressing	Waiting for CTA confirmation, Phase I	2020		
9	Placencare	Sinacell	Allogeneic placental extract	Mesotherapy	Waiting For inspection, to get the GMP license	–	–	–